WallStSmart

Cognizant Technology Solutions Corp Class A (CTSH)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 164% more annual revenue ($56.58B vs $21.41B). NVS leads profitability with a 23.9% profit margin vs 10.4%. CTSH appears more attractively valued with a PEG of 0.85. CTSH earns a higher WallStSmart Score of 67/100 (B-).

CTSH

Strong Buy

67

out of 100

Grade: B-

Growth: 4.7Profit: 7.0Value: 9.3Quality: 5.5
Piotroski: 2/9

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 3.3Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CTSHUndervalued (+76.7%)

Margin of Safety

+76.7%

Fair Value

$304.80

Current Price

$51.68

$253.12 discount

UndervaluedFair: $304.80Overvalued
NVSSignificantly Overvalued (-51.8%)

Margin of Safety

-51.8%

Fair Value

$110.12

Current Price

$146.03

$35.91 premium

UndervaluedFair: $110.12Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CTSH3 strengths · Avg: 8.7/10
P/E RatioValuation
11.3x10/10

Attractively priced relative to earnings

PEG RatioValuation
0.858/10

Growing faster than its price suggests

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$277.42B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

CTSH2 concerns · Avg: 3.5/10
EPS GrowthGrowth
3.6%4/10

3.6% earnings growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

NVS4 concerns · Avg: 2.5/10
Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

PEG RatioValuation
2.592/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : CTSH

The strongest argument for CTSH centers on P/E Ratio, PEG Ratio, Price/Book. PEG of 0.85 suggests the stock is reasonably priced for its growth.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : CTSH

The primary concerns for CTSH are EPS Growth, Piotroski F-Score.

Bear Case : NVS

The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

CTSH profiles as a value stock while NVS is a declining play — different risk/reward profiles.

CTSH carries more volatility with a beta of 0.80 — expect wider price swings.

CTSH is growing revenue faster at 5.8% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

CTSH scores higher overall (67/100 vs 51/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cognizant Technology Solutions Corp Class A

TECHNOLOGY · INFORMATION TECHNOLOGY SERVICES · USA

Cognizant is an American multinational technology company that provides business consulting, information technology and outsourcing services. It is headquartered in Teaneck, New Jersey, United States.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?